Skip to content

Depreciation at other companies

Stryker logo
StrykerSYK
$120M+14.3%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
LBR
LB Pharmaceuticals Inc Common StockLBRX
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
Axsome Therapeutics logo
Axsome TherapeuticsAXSM

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$887.88M+1,358%
Enterprise value$644.49M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's depreciation?
Alto Neuroscience (ANRO) reported depreciation of $184K in Q1 2026.
How has Alto Neuroscience's depreciation changed year-over-year?
Alto Neuroscience's depreciation increased by 7.6% year-over-year, from $171K to $184K.